Agios Pharmaceuticals Has Announced Exclusive Worldwide License Agreement For Alnylam Pharmaceuticals' Preclinical siRNA Targeting TMPRSS6 For Polycythemia Vera; Agios Will Pay An Upfront Of $17.5M And Up To $130M In Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals has entered into an exclusive worldwide license agreement for Alnylam Pharmaceuticals' preclinical siRNA targeting TMPRSS6 for Polycythemia Vera. Agios will pay an upfront of $17.5M and up to $130M in milestone payments.
August 04, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agios Pharmaceuticals has made a significant investment in Alnylam's preclinical siRNA, which could impact its short-term financials.
Agios Pharmaceuticals is making a significant upfront payment and committing to potential milestone payments, which could strain its short-term financials. However, the investment could pay off in the long term if the siRNA proves successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Alnylam Pharmaceuticals stands to gain financially from the licensing agreement with Agios Pharmaceuticals.
Alnylam Pharmaceuticals will receive an upfront payment and potential milestone payments from Agios Pharmaceuticals, which could boost its short-term financials. The deal also validates Alnylam's preclinical siRNA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100